Accelerating discovery of an efficacious plasmodium vivax multivalent multi-stage vaccine

Active Cooperative Agreement Awarded Last action

Award ID
U01AI155361
Recipient
Awarding agency
Obligated
$14,502,727

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 98% complete
Originally
Funding
  • $13,466,495.00 Federal
  • $1,036,232.00 Non-federal
Place of performance
Florida, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Plasmodium vivax is the second leading cause of malaria and the most prevalent cause of malaria outside of africa. The estimated cost of the global burden of vivax malaria is $1.4 - $4 billion per year and more people live at risk worldwide from p. Vivax than p. Falciparum. IT is endemic mostly in poor countries where access to affordable health care is lacking, which leads to lost adult productivity. Relapse infections from p. Vivax poses a special challenge to malaria elimination and eradication because of its ability to repeatedly restart blood-stage infections from hypnozoites - the dormant parasite that can persist in human livers from weeks to years after the sporozoite infection. Exacerbating the problem, p. Vivax transmission occurs prior to onset of clinical signs and treatment options to clear relapsing parasites in the dormant liver stage are limited. The goal of this U01 project is to accelerate vivax malaria vaccine development by validation of an optimal combination of p. Vivax target antigens in pre-erythrocytic stages. Our vaccine strategy seeks to validate candidate antigens that together can effectively inhibit sporozoite infection and block liver stage development, including blood stage breakthrough infection. Our strategy exploits our new in vitro functional assay for experimental studies of liver stage development of p. Vivax. We will pursue a structural vaccinology approach, using broadly neutralizing binding inhibitory antisera and monoclonal antibodies to identify and characterize the highest value immunogens and vaccine delivery method to design a multivalent vaccine to prevent and eliminate vivax malaria.

Transactions

Action Federal Non-federal Date
Amendment $0 $0
Amendment $882,985 $0
Amendment $882,985 $0
Amendment $96,505 $0
Amendment $96,505 $0
Amendment $868,542 $0
Amendment $868,542 $0
Amendment $868,542 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $975,499 $0
Amendment $975,499 $0
Amendment $975,499 $0
Amendment $975,499 $0
Amendment $975,499 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $975,965 $0
Amendment $975,965 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $1,036,232 $0
Original award $1,036,232 $1,036,232
Show all 29

Subawards

Subrecipient Amount Awarded
The Geneva Foundation Accelerating discovery of an efficacious Plasmodium vivax multivalent multi-stage vaccine $83,288
Institut Pasteur DU Cambodge Accelerating discovery of an efficacious plasmodium vivax multivalent multi-stage vaccine. $72,144
Mahidol University $85,164
The Johns Hopkins University $95,791
The Geneva Foundation $80,294
The Johns Hopkins University $98,080
Mahidol University Accelerating discovery of an efficacious plasmodium vivax multivalent multistage vaccine. $86,242
Institut Pasteur DU Cambodge $74,592

Quick answers

Who received award U01AI155361?

U01AI155361 was awarded to University Of South Florida by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on December 1, 2020.

How much is award U01AI155361 worth?

$14,502,727 has been obligated on U01AI155361: $13,466,495 in federal funding and $1,036,232 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login